Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

If you haven’t read it yet, an excellent commentary was published in Medscape this week by a cardiologist and obesity specialist. He pushes back against rampant misinformation around compounded GLP-1s. Dr. Eldav Einav distinguishes between counterfeit and compounded products, and he makes a great point — by completely dismissing compounded medications, prescribers and others may be unintentionally bolstering the black market. How? Patients may feel their only option to access these medications is going outside of the legitimate health care system. APC worked with Dr. Einav to prepare the piece. Please share it with prescribers in your area.